Call Options on ALXN on 10/28/2019

Alexion Pharmaceuticals, Inc. (ALXN) is a biopharmaceutical company.

It develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.

It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency.

In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder.

Further, it develops ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 (SYNT001), which is in Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. 

Shares have risen above an overhead resistance following the company's latest quarterly report. On October 23rd, Alexion Pharm (ALXN) reported 3rd Quarter September 2019 earnings of $2.75 per share on revenue of $1.3 billion. The consensus earnings estimate was $2.47 per share on revenue of $1.2 billion.  Revenue grew 23.0% on a year-over-year basis.

The company said it now expects 2019 non-GAAP earnings of $10.25 to $10.40 per share on revenue of $4.86 billion to $4.89 billion. The company's previous guidance was earnings of $9.65 to $9.85 per share on revenue of $4.75 billion to $4.80 billion and the current consensus earnings estimate is $9.94 per share on revenue of $4.85 billion for the year ending December 31, 2019.

Last Trade: $104.00

Trading Range: $92.56 to $141.86

Trade Buy 1 November $104.00 Call at $2.50 For a net debit of $2.50 Profit/Loss Analysis Breakeven at $106.50 Maximum profit is unbounded Maximum loss is ($250.00) at strike of $104.00 Closing Summary Sold 1 November $104.00 Call at $5.50

Position closed on 11/6/2019 at price of $5.50 with a 120.00% gain in 9 days.

Updates

11/6/2019 11:10:57 AM

ALXN call option sold for $5.50

Back to Portfolio